Etalocib sodium

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameEtalocib sodium
Drug Alias NameEtalocibum艾他洛西钠艾他洛西VML-295LY-293111Na +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukotriene B4 receptor antagonistsPeroxisome proliferator-activated receptor γ agonistsArachidonate 5-lipoxygenase inhibitors
TargetsLeukotriene B4 receptorPeroxisome proliferator-activated receptor γArachidonate 5-lipoxygenase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And CompanyNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia